TherapeuticsMD, Inc. operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen. The company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD and BocaGreenMD brands. It markets its products primarily through a direct national sales force to health care providers in the OB/GYN market space. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone561-961-1900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.10 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions
What is TherapeuticsMD's stock symbol?
TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."
How were TherapeuticsMD's earnings last quarter?
TherapeuticsMD Inc (NASDAQ:TXMD) posted its earnings results on Thursday, February, 21st. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). The company earned $5.09 million during the quarter, compared to analysts' expectations of $5.03 million. TherapeuticsMD had a negative return on equity of 127.34% and a negative net margin of 823.71%. View TherapeuticsMD's Earnings History.
When is TherapeuticsMD's next earnings date?
What price target have analysts set for TXMD?
3 Wall Street analysts have issued twelve-month price objectives for TherapeuticsMD's shares. Their predictions range from $11.00 to $27.00. On average, they anticipate TherapeuticsMD's share price to reach $17.3333 in the next year. This suggests a possible upside of 213.4% from the stock's current price. View Analyst Price Targets for TherapeuticsMD.
What is the consensus analysts' recommendation for TherapeuticsMD?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TherapeuticsMD.
What are Wall Street analysts saying about TherapeuticsMD stock?
Here are some recent quotes from research analysts about TherapeuticsMD stock:
- 1. According to Zacks Investment Research, "TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. " (2/28/2019)
- 2. Cantor Fitzgerald analysts commented, "We reiterate our OW rating. The execution behind the launches of Annovera is underappreciated, in our view, and we think peak sales could exceed modest expectations for three drugs that target large unmet needs. Valuation Summary We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of EV/EBITDA and DCF analysis to arrive at our 12-month PT of $27." (1/21/2019)
Has TherapeuticsMD been receiving favorable news coverage?
Media stories about TXMD stock have trended somewhat positive recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. TherapeuticsMD earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term.
Are investors shorting TherapeuticsMD?
TherapeuticsMD saw a increase in short interest during the month of February. As of February 28th, there was short interest totalling 72,470,913 shares, an increase of 2.5% from the February 15th total of 70,696,230 shares. Based on an average daily trading volume, of 4,606,687 shares, the days-to-cover ratio is currently 15.7 days. Approximately 36.5% of the shares of the stock are short sold. View TherapeuticsMD's Current Options Chain.
Who are some of TherapeuticsMD's key competitors?
Some companies that are related to TherapeuticsMD include Array Biopharma (ARRY), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), GW Pharmaceuticals PLC- (GWPH), FibroGen (FGEN), Horizon Pharma (HZNP), Amneal Pharmaceuticals (AMRX), Taro Pharmaceutical Industries (TARO), TESARO (TSRO), ACADIA Pharmaceuticals (ACAD), Agios Pharmaceuticals (AGIO), HUTCHISON CHINA/S (HCM), Blueprint Medicines (BPMC), Evotec (EVTCY) and Ultragenyx Pharmaceutical (RARE).
What other stocks do shareholders of TherapeuticsMD own?
Who are TherapeuticsMD's key executives?
TherapeuticsMD's management team includes the folowing people:
- Mr. Robert G. Finizio, Co-Founder, CEO & Director (Age 48)
- Mr. John C. K. Milligan IV, Pres, Sec. & Director (Age 57)
- Dr. Brian A. Bernick, Co-Founder, Chief Clinical Officer & Director (Age 51)
- Mr. Daniel Alan Cartwright, CFO & Treasurer (Age 61)
- Mr. Mitchell L. Krassan, Exec. VP & Chief Strategy Officer (Age 53)
Who are TherapeuticsMD's major shareholders?
TherapeuticsMD's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Bank of New York Mellon Corp (12.82%), FMR LLC (7.60%), BlackRock Inc. (7.02%), Millennium Management LLC (1.20%), Stifel Financial Corp (1.02%) and Northern Trust Corp (0.96%). Company insiders that own TherapeuticsMD stock include Brian Bernick, Daniel A Cartwright, John CK Iv Milligan, Jules A Musing, Robert G Finizio and Tommy G Thompson. View Institutional Ownership Trends for TherapeuticsMD.
Which institutional investors are selling TherapeuticsMD stock?
TXMD stock was sold by a variety of institutional investors in the last quarter, including TD Asset Management Inc., Raymond James & Associates, Bank of Montreal Can, MetLife Investment Advisors LLC, Natixis Advisors L.P., First Trust Advisors LP, Mengis Capital Management Inc. and Northern Trust Corp. Company insiders that have sold TherapeuticsMD company stock in the last year include Brian Bernick, Daniel A Cartwright, John CK Iv Milligan, Jules A Musing and Robert G Finizio. View Insider Buying and Selling for TherapeuticsMD.
Which institutional investors are buying TherapeuticsMD stock?
TXMD stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, Frontier Capital Management Co. LLC, Norges Bank, BlackRock Inc., Stifel Financial Corp, 1492 Capital Management LLC and Public Employees Retirement Association of Colorado. View Insider Buying and Selling for TherapeuticsMD.
How do I buy shares of TherapeuticsMD?
Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is TherapeuticsMD's stock price today?
One share of TXMD stock can currently be purchased for approximately $5.53.
How big of a company is TherapeuticsMD?
TherapeuticsMD has a market capitalization of $1.33 billion and generates $16.10 million in revenue each year. The company earns $-132,620,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis.
What is TherapeuticsMD's official website?
How can I contact TherapeuticsMD?
TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]
MarketBeat Community Rating for TherapeuticsMD (NASDAQ TXMD)
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
